UK markets closed

Athenex, Inc. (ATNX)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
0.4330+0.0236 (+5.76%)
At close: 04:00PM EDT
0.4287 -0.00 (-0.99%)
After hours: 07:42PM EDT

Athenex, Inc.

Conventus Building
Suite 600 1001 Main Street
Buffalo, NY 14203
United States
716 427 2950
https://www.athenex.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full-time employees652

Key executives

NameTitlePayExercisedYear born
Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.Chairman & CEO547.73k23.35k1960
Mr. Jeffrey M. YordonCOO & Pres of Athenex Pharmaceutical Division424.72kN/A1949
Dr. Daniel Lang M.D.Pres of Athenex Cell Therapy333.17kN/A1966
Dr. Allen BarnettCo-Founder & Pres EmeritusN/AN/AN/A
Mr. Joe Annoni C.F.A.Chief Financial OfficerN/AN/AN/A
Caileigh DoughertyDirector of Investor RelationsN/AN/AN/A
Ms. Jacqueline LiVP of Alliance Management & Corp. Devel.N/AN/AN/A
Mr. John W. MattheiVP of HRN/AN/AN/A
Dr. David CutlerDeputy Chief Medical Officer of Biologics & Cell TherapyN/AN/AN/A
Mr. Timothy CookChief Bus. & Commercial Officer of Proprietary DrugsN/AN/A1962
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company is developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product, which is in a phase I clinical trial for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinomas, as well as TCRT-ESO-A2, an autologous T cell receptor (TCR)-T cell therapy that is in phase 1 clinical trial for solid tumors. Further, it is developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York.

Corporate governance

Athenex, Inc.’s ISS governance QualityScore as of 30 June 2022 is 7. The pillar scores are Audit: 5; Board: 8; Shareholder rights: 8; Compensation: 3.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.